AUPR395801A0 - Antibodies against cancer - Google Patents

Antibodies against cancer

Info

Publication number
AUPR395801A0
AUPR395801A0 AUPR3958A AUPR395801A AUPR395801A0 AU PR395801 A0 AUPR395801 A0 AU PR395801A0 AU PR3958 A AUPR3958 A AU PR3958A AU PR395801 A AUPR395801 A AU PR395801A AU PR395801 A0 AUPR395801 A0 AU PR395801A0
Authority
AU
Australia
Prior art keywords
antibodies against
against cancer
cancer
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AUPR3958A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Austin Research Institute
Original Assignee
Austin Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Austin Research Institute filed Critical Austin Research Institute
Priority to AUPR3958A priority Critical patent/AUPR395801A0/en
Publication of AUPR395801A0 publication Critical patent/AUPR395801A0/en
Priority to EP02706533A priority patent/EP1383801A4/en
Priority to NZ528624A priority patent/NZ528624A/xx
Priority to CNA2008101103851A priority patent/CN101310770A/zh
Priority to JP2002576291A priority patent/JP4854912B2/ja
Priority to CA002442318A priority patent/CA2442318A1/en
Priority to US10/470,013 priority patent/US7318924B2/en
Priority to PCT/AU2002/000362 priority patent/WO2002077033A1/en
Priority to CNB028073177A priority patent/CN100457781C/zh
Priority to AU2002240719A priority patent/AU2002240719B2/en
Priority to KR1020037012528A priority patent/KR100909290B1/ko
Priority to AU2007201587A priority patent/AU2007201587A1/en
Priority to US11/943,191 priority patent/US20090123470A1/en
Priority to JP2008188842A priority patent/JP2009024014A/ja
Priority to US12/619,053 priority patent/US20100119514A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AUPR3958A 2001-03-26 2001-03-26 Antibodies against cancer Abandoned AUPR395801A0 (en)

Priority Applications (15)

Application Number Priority Date Filing Date Title
AUPR3958A AUPR395801A0 (en) 2001-03-26 2001-03-26 Antibodies against cancer
AU2002240719A AU2002240719B2 (en) 2001-03-26 2002-03-26 Antibodies against cancer
US10/470,013 US7318924B2 (en) 2001-03-26 2002-03-26 Antibodies against cancer
CNB028073177A CN100457781C (zh) 2001-03-26 2002-03-26 抗癌抗体
CNA2008101103851A CN101310770A (zh) 2001-03-26 2002-03-26 抗癌抗体
JP2002576291A JP4854912B2 (ja) 2001-03-26 2002-03-26 癌に対する抗体
CA002442318A CA2442318A1 (en) 2001-03-26 2002-03-26 Antibodies against cancer
EP02706533A EP1383801A4 (en) 2001-03-26 2002-03-26 ANTIBODY AGAINST CANCER
PCT/AU2002/000362 WO2002077033A1 (en) 2001-03-26 2002-03-26 Antibodies against cancer
NZ528624A NZ528624A (en) 2001-03-26 2002-03-26 Antibodies against cancer
KR1020037012528A KR100909290B1 (ko) 2001-03-26 2003-09-26 항암 항체
AU2007201587A AU2007201587A1 (en) 2001-03-26 2007-04-11 Antibodies against cancer
US11/943,191 US20090123470A1 (en) 2001-03-26 2007-11-20 Antibodies Against Cancer
JP2008188842A JP2009024014A (ja) 2001-03-26 2008-07-22 癌に対する抗体
US12/619,053 US20100119514A1 (en) 2001-03-26 2009-11-16 Antibodies Against Cancer

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AUPR3958A AUPR395801A0 (en) 2001-03-26 2001-03-26 Antibodies against cancer

Publications (1)

Publication Number Publication Date
AUPR395801A0 true AUPR395801A0 (en) 2001-04-26

Family

ID=3827964

Family Applications (3)

Application Number Title Priority Date Filing Date
AUPR3958A Abandoned AUPR395801A0 (en) 2001-03-26 2001-03-26 Antibodies against cancer
AU2002240719A Ceased AU2002240719B2 (en) 2001-03-26 2002-03-26 Antibodies against cancer
AU2007201587A Abandoned AU2007201587A1 (en) 2001-03-26 2007-04-11 Antibodies against cancer

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2002240719A Ceased AU2002240719B2 (en) 2001-03-26 2002-03-26 Antibodies against cancer
AU2007201587A Abandoned AU2007201587A1 (en) 2001-03-26 2007-04-11 Antibodies against cancer

Country Status (9)

Country Link
US (1) US7318924B2 (OSRAM)
EP (1) EP1383801A4 (OSRAM)
JP (2) JP4854912B2 (OSRAM)
KR (1) KR100909290B1 (OSRAM)
CN (2) CN101310770A (OSRAM)
AU (3) AUPR395801A0 (OSRAM)
CA (1) CA2442318A1 (OSRAM)
NZ (1) NZ528624A (OSRAM)
WO (1) WO2002077033A1 (OSRAM)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0020953D0 (en) 2000-08-24 2000-10-11 Smithkline Beecham Biolog Vaccine
SK14432003A3 (sk) 2001-04-26 2004-07-07 Biogen, Inc. Protilátka špecifická pre Cripto, kompozícia obsahujúca takúto protilátku a jej použitie
US7582299B2 (en) 2001-04-26 2009-09-01 Biogen Idec Ma Inc. Cripto-specific antibodies
AU2003301619A1 (en) * 2002-10-23 2004-05-13 Exelixis, Inc. MBMs AS MODIFIERS OF BRANCHING MORPHOGENESIS AND METHODS OF USE
EP1624073A4 (en) * 2003-04-03 2006-05-17 Oncorex Inc DRUG
WO2005000898A2 (en) * 2003-06-27 2005-01-06 Biogen Idec Ma Inc. Use of hydrophobic-interaction-chromatography or hinge-region modifications for the production of homogeneous antibody-solutions
CA2539116C (en) * 2003-09-15 2014-11-18 Research Development Foundation Cripto antagonism of activin and tgf-b signaling
EP2591786B1 (en) 2003-10-16 2017-04-12 Cancure Limited Immunomodulating compositions and uses therefor
EP2311880A3 (en) * 2005-01-05 2011-07-27 Biogen Idec MA Inc. Cripto binding molecules
US7939056B2 (en) * 2005-11-14 2011-05-10 The Brigham And Women's Hospital, Inc. Interleukin-10 compositions for the treatment of adenocarcinomas
EP2162152A2 (en) * 2007-06-01 2010-03-17 Biogen Idec MA, Inc. Cripto binding molecules
EP2303319B1 (en) 2008-06-20 2016-10-05 Duke University Compositions, methods and kits for eliciting an immune response
KR100973029B1 (ko) * 2008-10-07 2010-08-11 박지운 알루미늄 합금 가로등 등주
CN102272157B (zh) * 2008-11-07 2015-11-25 研究发展基金会 用于抑制cripto/grp78复合物形成和信号的组合物和方法
JP5990752B2 (ja) * 2011-01-31 2016-09-14 オリンパス株式会社 抗体療法の効果増強剤
TWI582112B (zh) 2011-04-21 2017-05-11 西雅圖遺傳學公司 新穎結合劑－藥物接合物（ＡＤＣｓ）及其用途（二）
JP6721507B2 (ja) 2013-12-23 2020-07-15 バイエル・ファルマ・アクティエンゲゼルシャフト Ｋｓｐ阻害剤との抗体薬物複合体（ａｄｃ）
AU2016250900B2 (en) * 2015-04-20 2022-03-17 GlyTherix Ltd. Therapeutic antibodies and uses thereof
SG10201908685QA (en) 2015-06-22 2019-10-30 Bayer Pharma AG Antibody drug conjugates (adcs) and antibody prodrug conjugates (apdcs) with enzymatically cleavable groups
CA2990300A1 (en) 2015-06-23 2016-12-29 Hans-Georg Lerchen Site specific homogeneous conjugates with ksp inhibitors
WO2017060322A2 (en) 2015-10-10 2017-04-13 Bayer Pharma Aktiengesellschaft Ptefb-inhibitor-adc
AU2017236431A1 (en) 2016-03-24 2018-09-27 Bayer Pharma Aktiengesellschaft Prodrugs of cytotoxic active agents having enzymatically cleavable groups
CA3027445A1 (en) 2016-06-15 2017-12-21 Bayer Pharma Aktiengesellschaft Specific antibody-drug-conjugates (adcs) with ksp inhibitors and anti-cd123-antibodies
WO2018114804A1 (de) 2016-12-21 2018-06-28 Bayer Pharma Aktiengesellschaft Spezifische antikörper-wirkstoff-konjugate (adcs) mit ksp-inhibitoren
EP3558386A1 (de) 2016-12-21 2019-10-30 Bayer Aktiengesellschaft Prodrugs von cytotoxischen wirkstoffen mit enzymatisch spaltbaren gruppen
MX2019007641A (es) 2016-12-21 2019-09-09 Bayer Pharma AG Conjugados de ligando-farmaco (adcs) con grupos escindibles enzimaticamente.
CN109744199A (zh) * 2017-11-08 2019-05-14 南京艾莫瑞生物科技有限公司 一种肿瘤细胞异种移植斑马鱼模型、其构建方法及应用
JP6761889B1 (ja) * 2019-11-11 2020-09-30 株式会社Ｇｓｐエンタープライズ 抗ヒトＣｒｉｐｔｏ−１抗体

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5171665A (en) 1989-04-17 1992-12-15 Oncogen Monoclonal antibody to novel antigen associated with human tumors
US5256643A (en) 1990-05-29 1993-10-26 The Government Of The United States Human cripto protein
US5264557A (en) * 1991-08-23 1993-11-23 The United States Of America As Represented By The Department Of Health And Human Services Polypeptide of a human cripto-related gene, CR-3
US5981215A (en) 1995-06-06 1999-11-09 Human Genome Sciences, Inc. Human criptin growth factor
DE69738868D1 (de) 1996-05-22 2008-09-11 Viventia Biotech Inc Odieren, und deren verwendung zur vorbeugung und zum nachweis von krebs
IL125608A0 (en) * 1998-07-30 1999-03-12 Yeda Res & Dev Tumor associated antigen peptides and use of same as anti-tumor vaccines
ID29246A (id) 1999-03-11 2001-08-16 Ardenia Investments Ltd Senyawa-senyawa baru untuk pengobatan kanker
US6333410B1 (en) 2000-08-18 2001-12-25 Immunogen, Inc. Process for the preparation and purification of thiol-containing maytansinoids
GB0020953D0 (en) * 2000-08-24 2000-10-11 Smithkline Beecham Biolog Vaccine
AU9272401A (en) 2000-09-18 2002-03-26 Biogen Inc Cripto mutant and uses thereof
US7582299B2 (en) 2001-04-26 2009-09-01 Biogen Idec Ma Inc. Cripto-specific antibodies
SK14432003A3 (sk) 2001-04-26 2004-07-07 Biogen, Inc. Protilátka špecifická pre Cripto, kompozícia obsahujúca takúto protilátku a jej použitie

Also Published As

Publication number Publication date
CN100457781C (zh) 2009-02-04
US20040176576A1 (en) 2004-09-09
CN101310770A (zh) 2008-11-26
KR20040010613A (ko) 2004-01-31
NZ528624A (en) 2006-03-31
US7318924B2 (en) 2008-01-15
AU2007201587A1 (en) 2007-05-03
WO2002077033A1 (en) 2002-10-03
CA2442318A1 (en) 2002-10-03
KR100909290B1 (ko) 2009-07-24
JP2009024014A (ja) 2009-02-05
AU2002240719B2 (en) 2007-01-11
EP1383801A1 (en) 2004-01-28
JP4854912B2 (ja) 2012-01-18
EP1383801A4 (en) 2005-06-01
CN1639194A (zh) 2005-07-13
JP2004534741A (ja) 2004-11-18

Similar Documents

Publication Publication Date Title
AUPR395801A0 (en) Antibodies against cancer
AU2002256895A1 (en) Anti-TRAIL-R antibodies
AU2002247304A1 (en) Anti-neovasculature preparations for cancer
AU2002360766A1 (en) Methods for cancer imaging
AU2002365649A1 (en) Anti-dota antibody
AUPR969501A0 (en) Forfaiting transactions
AU2001290860A1 (en) Spas-1 cancer antigen
AU2002349543A1 (en) Tumor antigens
AU2002226571A1 (en) Biligands
AU2001100406A4 (en) DriverSMS
AU2002313073A1 (en) Phytocystatin
AU2002306319A1 (en) Tumor antigen
AU2002363198A1 (en) Tumor antigen
AUPR589001A0 (en) An antibody cancer therapeutic
AU2002302838A1 (en) Cancer associated protein
AU2002257925A1 (en) Numberplates
HK1062400A (en) Anti-neovasculature preparations for cancer
AU2002355220A1 (en) Cancer diagnostics
HK1067862A (zh) 抗体定位化合物
AUPR726301A0 (en) Payment
AU2001100338A4 (en) Sunglove
AU2001100214A4 (en) Dolly-trolley
AU2001100532A4 (en) FonePark
AU2001100522A4 (en) e-Trans
AU2002100746A4 (en) Adrail